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Abstract
Background This study aims to investigate whether
increased awareness of breast cancer, due to a positive
family history (FH), reduces diagnostic, therapeutic, and
survival differences between women of low versus high
socio-economic status (SES).
Methods All breast cancer patients registered between
1990 and 2005 at the population-based Geneva Cancer
Registry were included. With multivariate logistic and Cox
regression analysis, we estimated the impact of SES and
FH on method of detection, treatment, and mortality from
breast cancer.
Results SES discrepancies in method of detection and
suboptimal treatment, as seen among women without a FH,
disappeared in the presence of a positive FH. SES differ-
ences in stage and survival remained regardless of the
presence of a positive FH. Overall, positive FH was asso-
ciated with better survival. This effect was the strongest in
women of high SES (age-adjusted Hazard Ratio [HRageadj]
0.54 [0.3–1.0]) but less pronounced in women of middle
(0.77 [0.6–1.0]), and absent in women of low SES (0.80
[0.5–1.2]).
Conclusion A positive FH of breast cancer may reduce
SES differences in access to screening and optimal treat-
ment. However, even with better access to early detection
and optimal treatment, women of low SES have higher
risks of death from their disease than those of high SES.
Keywords Breast cancer  Social disparities 
Family history  Survival  Early detection
Introduction
A positive family history of breast or ovarian cancer is a
risk factor for breast cancer [1, 2]. Several studies have
indicated that a positive family history may lead to better
compliance with early detection strategies, including
mammography screening [3–6]. This could be due to the
fact that women with affected family members are more
aware of the risk of the disease and its associated com-
plications and, therefore, more motivated to participate in
prevention and screening activities. There is also evidence
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that breast cancer patients with affected family members
hold less incorrect beliefs regarding cancer treatment and,
as a result, receive more adequate or more complete ther-
apy [7, 8]. Having experience with breast cancer treatment
in family members may allow patients to make better
informed decisions regarding treatment.
Socio-economic status (SES) is an important prog-
nostic factor in breast cancer, as breast cancer patients of
low SES have a significantly higher risk of death from
their disease than women of high SES [9–12]. In a pre-
vious study, we showed that the excess mortality risk is
partly attributable to impaired access to, and lower par-
ticipation in mammography screening programs, unfa-
vorable stage distribution at diagnosis, and suboptimal
treatment [12].
It is, therefore, in women of low SES that presence of a
family history could potentially have the largest effect in
terms of better access to screening and optimal treatment.
In this population-based study, we examined whether the
impact of a positive family history on method of detection,
stage at diagnosis, treatment, and survival was different
across the different socio-economic groups in the Swiss
canton of Geneva.
Methods
We used data from the Geneva cancer registry, which
records all incident cancers occurring in the population of
the Geneva canton (*420,000 inhabitants) since 1970. It
collects information from various sources and is considered
accurate, as it is attested by its very low percentage (\2%)
of cases recorded from death certificates only [13]. All
hospitals, pathology laboratories, and private practitioners
in the canton are requested to report all cancer cases.
Trained tumor registrars systematically abstract data from
medical and laboratory records. Physicians regularly
receive inquiry forms to complete missing clinical and
therapeutic data. Recorded data include socio-demographic
information, method of diagnosis, type of confirmation,
tumor characteristics coded according to the International
Classification of Diseases for Oncology [14], stage of
disease at diagnosis, hormone receptor status, and treat-
ment during the first 6 months after diagnosis. The registry
regularly assesses survival, taking as reference date the
date of confirmation of diagnosis or the date of hospital-
ization (if it preceded the diagnosis and was related to the
disease). In addition to passive follow-up (standard exam-
ination of death certificates and hospital records), active
follow-up is performed yearly using the files of the Can-
tonal Population Office (office in charge of the registration
of the resident population). Cause of death is taken from
clinical files.
In 1999, the Geneva Cancer Registry has set up a
Familial Breast Cancer Registry by including detailed
family history of cancer for all women diagnosed with
invasive breast cancer in the Geneva population [15].
Family history of cancer is abstracted from medical records
and classified as positive if at least one-first- or second-
degree relative had been diagnosed with breast or ovarian
cancer. We decided to classify family histories of only
ovarian cancer as positive as well, because ovarian cancer in
family members is increasingly being mentioned as a risk
factor for breast cancer on lay websites and online breast
cancer risk calculators [16–18].
All other family histories were classified as negative.
For breast cancer patients diagnosed between 1990 and
1999, family history was collected retrospectively, using
information from medical records from the public univer-
sity hospitals and private physicians. For 90% of the breast
cancer patients, information on family history was
obtained, and the accuracy of this retrospectively retrieved
information has been validated [19]. Since 1999, family
histories of breast and ovarian cancer are collected pro-
spectively for all breast cancer patients.
SES was based on the woman’s last occupation or, for
the unemployed, that of the spouse. The Geneva cancer
registry systematically retrieves the patient’s last occupa-
tion from the files of the Cantonal Population Office. We
used the classification of vital statistics that includes 12
major groups subdivided into 40 sub-major groups and 130
minor groups [20]. Occupational subgroups were classified
into SES indicators in 7 levels based on the Social Classes
of the British Registrar General [21]. For the purpose of
this study, we regrouped SES in 4 levels only: low (manual
employees, skilled, and unskilled workers, including
farmers), middle (nonmanual employees and administra-
tive staff), high (professionals, executives, administrators,
entrepreneurs), and unknown.
For staging, we used the pathological pTNM (tumor
node metastasis) classification system or, when not avail-
able, the clinical cTNM classification [22]). Stage was
classified into five groups: stage 0/I (T in situ or T1 and
N0), stage II (T0 or T1 and N1, T2, and N0 or N1, T3, and
N0), stage III (T0 or T1 or T2 and N2, T3, and N1 or N2,
T4, and any N, any T and N3), stage IV (M1), and
unknown. Tumor differentiation (grade) was classified as
well differentiated (grade 1), moderately differentiated
(grade 2), and poorly differentiated (grade 3). Estrogen
receptor status was taken from the pathology report and
classified as positive when C10% of the cancer cells
expressed estrogen receptors.
Method of tumor detection was extracted from medical
records and categorized as surveillance of healthy individ-
uals (i.e., mammography or ultrasound screening or peri-
odic clinical examination of asymptomatic individuals),
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symptoms, breast self examination, and other. Loco-regio-
nal therapy was categorized as breast-conserving surgery
followed by radiotherapy, mastectomy, and other (including
no surgery or tumorectomy without radiotherapy). Use of
chemotherapy and hormone therapy was categorized as yes
versus no.
In the current study, we included resident women
diagnosed with in situ or invasive breast cancer between
1990 and 2005 (n = 5593). Patients without information
on SES (n = 1077), family history of breast or ovarian
cancer (n = 386), or both (n = 184) were excluded,
leaving us with a dataset of 3,946 breast cancer patients.
We evaluated socio-economic differences in demo-
graphics, tumor characteristics, diagnostic, and therapeutic
variables for women of increased versus low familial risk
with chi square testing. With logistic regression analysis,
we estimated the effect of family history on (1) likelihood
of having tumor detected by surveillance (i.e., mam-
mography, ultrasound, or clinical examination of asymp-
tomatic individuals), (2) likelihood to present with early
(stage 0/I) disease at diagnosis, (3) likelihood to receive
inadequate loco-regional treatment (i.e., no surgery or
tumorectomy without radiotherapy) and (4) likelihood to
receive chemotherapy, for each of the SES strata. In this
analysis, we adjusted for age only, in order not to over
adjust for family-history-related variables. Effect modifi-
cation of the effect of family history on these four vari-
ables by SES was tested by adding interaction terms to
the logistic regression models. With Kaplan–Meier anal-
ysis, we calculated breast cancer survival rates for women
at high versus low familial risk and used Logrank testing
to evaluate survival differences. We used univariate Cox
proportional hazards analysis to identify differences in
breast cancer mortality risk between women of increased
versus low familial risk for the three SES subgroups.
With multivariate analysis, we evaluated to which extent
survival differences between women at low versus
increased familial risk were attributable to differences in
method of detection, stage at diagnosis, loco-regional, and
systemic treatment. Data were analyzed with SPSS (ver-
sion 17.0), and differences were considered significant at
a two-sided p \ 0.05.
Results
Of the 3,946 patients included in this study, 1,132 (28.7%)
had a family history of breast cancer. On the whole, 649
(16%) were of high, 2,463 (62%) of middle, and 834 (21%)
of low SES. Prevalence of a positive family history differed
across the three SES groups: 34% of high, 29% of middle,
and 24% of low SES women had affected first- or second-
degree family members (p \ 0.001).
For all SES groups, women with a family history of
breast cancer were on average 2 years younger than those
without a family history: 55.1 versus 57.1 years (p =
0.035) for women of high SES, 56.7 versus 59.0 years
(p \ 0.001) for women of middle SES, and 60.4 versus
62.2 years (p = 0.103) for women of low SES.
Among women without a family history of breast cancer,
there were strong socio-economic differences in method of
detection (Table 1). Specifically, women of high SES were
much more likely to have their tumor detected by surveil-
lance than those of low SES (37 versus 23%, respectively;
p \ 0.001). In the presence of a positive family history,
these socio-economic discrepancies were no longer present
(p = 0.50).
Socio-economic differences in stage distribution were
not affected by the presence of a positive family history.
Less women of low SES presented with early stage disease
than those of high SES, regardless of their positive family
history. Women of low SES were also slightly less likely to
present with well-differentiated tumors, which was the case
for both women with and without a family history. There
were no socio-economic differences in estrogen receptor,
neither for women with nor for those without a family
history of breast cancer (Table 1).
Among women without a family history, a significantly
larger proportion of high SES women had received breast-
conserving surgery than of low SES women (Table 2). In
the presence of a family history, this difference was less
pronounced and no longer significant. Similarly, among
women without a family history, those of low SES received
chemotherapy significantly less frequently than those of
high SES. In the presence of a family history, socio-eco-
nomic differences in use of chemotherapy disappeared.
SES was not related to use of hormone therapy, neither for
women with nor for those without a family history of breast
cancer.
Overall, presence of a family history increased the
likelihood of having tumors detected by surveillance (age-
adjusted HR [HRageadj] 1.32, 95% CI 1.1–1.5; Table 3).
This effect was the strongest among women of low SES
(HRageadj 1.60, 95% CI 1.1–2.3) and absent among women
of high SES (HRageadj 1.07, 95% CI 0.8–1.5. There was no
significant interaction between family history and SES in
relation to method of tumor detection.
Family history of breast cancer did not increase the
likelihood of being diagnosed with early stage disease,
neither for all women (HRageadj 1.00 [0.9–1.2]) nor for the
different socio-economic strata: HRageadj 1.08 [0.8–1.5] for
women of high SES, HRageadj 0.95 [0.08–1.1] for women of
middle SES and HRageadj 0.98 [0.7–1.4] for women of low
SES.
Women with a family history of breast cancer were
significantly less likely to receive inadequate loco-regional
Cancer Causes Control (2009) 20:1689–1696 1691
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treatment (i.e., no surgery or tumorectomy without radio-
therapy; HRageadj 0.68, 95% CI 0.5–0.9). This effect was
similar among the different SES strata, and only significant
for women of middle SES (Table 3). Overall, family his-
tory did not alter the likelihood of chemotherapy pre-
scription. However, in the subgroup of women with low
SES, those with a positive family history were significantly
more likely to be treated with chemotherapy (HRageadj 1.40,
95% CI 1.0–2.1).
Overall, breast cancer patients with a positive family
history had a lower risk of death from their disease than
those without a family history (unadjusted HR [HRunadj]
0.69, 95% CI 0.6–0.9; Table 4). After adjustment for age,
method of detection, estrogen receptor status, grade, loco-
regional, and systemic therapy, a positive family history
was still associated with a reduced breast cancer mortality
risk (HRadj 0.81, 95% CI 0.6–1.0).
Results by SES subgroup suggest that women of high
SES had the highest mortality risk reduction associated with
a positive family history (HRunadj 0.48, 95% CI 0.3–0.9),
while in women of low SES, a positive family history did
not significantly affect mortality risk (HRunadj 0.77, 95% CI
0.5–1.2). After adjustment, there was still a trend toward
lower mortality risk among women with a positive family
history, in particular among women of high SES. However,
the results were no longer significant.
Discussion
Women at increased perceived risk of breast cancer (often
due to an increased familial risk) experience lower barriers
to mammography screening and are, in the case of breast
symptoms, more likely to seek timely consultation of
specialists [5, 6, 23]. They hold less inaccurate beliefs
toward cancer treatment, they feel more comfortable with
treatment decisions and are more likely to receive adjuvant
therapy [6, 7, 23, 24].
Table 1 Patient and tumor characteristics of patients with versus without a family history of breast cancer by socio-economic status (SES)
Negative family history (n = 2,814) Positive family history (n = 1,132)
High SES
(n = 429)
Middle SES
(n = 1,748)
Low SES
(n = 637)
High SES
(n = 220)
Middle SES
(n = 715)
Low SES
(n = 197)
Method of detection
Surveillancea 157 (37%) 571 (33%) 148 (23%) 82 (37%) 272 (38%) 64 (33%)
Symptoms 89 (21%) 403 (23%) 178 (28%) 32 (15%) 134 (19%) 37 (19%)
BSEb 139 (32%) 523 (30%) 188 (30%) 80 (36%) 226 (32%) 73 (37%)
Other 37 (9%) 235 (13%) 114 (18%) 24 (11%) 75 (11%) 23 (12%)
Unknown 7 (2%) 16 (1%) 9 (1%) 2 (1%) 8 (1%) 0 (0%)
p \ 0.001 p = 0.501
TNM stage
In situ/I 208 (49%) 781 (45%) 230 (36%) 111 (50%) 312 (44%) 71 (35%)
II 166 (39%) 693 (40%) 259 (41%) 89 (41%) 301 (42%) 88 (45%)
III/IV 37 (9%) 223(13%) 122 (19%) 19 (9%) 78 (13%) 33 (17%)
Unknown 18 (4%) 51 (3%) 21 (3%) 1 (0.5%) 24 (3%) 5 (3%)
p \ 0.000 p = 0.008
Differentiation
Good 108 (25%) 478 (27%) 131 (21%) 54 (25%) 183 (26%) 42 (21%)
Moderate 188 (44%) 686 (39%) 255 (40%) 94 (43%) 308 (43%) 82 (42%)
Poor 80 (19%) 370(21%) 149 (23%) 56 (26%) 161 (23%) 44 (22%)
Unknown 53 (12%) 214 (12%) 102 (16%) 16 (7%) 63 (9%) 29 (15%)
p = 0.015 p = 0.88
ER statusc
Negative 47 (11%) 210 (12%) 76 (12%) 33 (15%) 82 (12%) 27 (14%)
Positive 273 (64%) 1,061 (61%) 341 (54%) 144 (66%) 495 (69%) 126 (64%)
Unknown 109 (25%) 477 (27%) 220 (35%) 43 (20%) 138 (19%) 44 (22%)
p = 0.439 p = 0.277
a Including mammography, ultrasound or MRI screening, and periodic clinical breast examination
b Breast self examination
c Estrogen receptor status
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The current study confirms that a positive family history
influences method of detection and treatment of breast
cancer, especially in patients of low SES. In general, low
SES is associated with impaired access to screening and
early detection, as well as suboptimal loco-regional and
systemic treatment [12]. Our results show that women of
Table 2 Treatment characteristics of patients with versus without a family history of breast cancer by socio-economic status
Negative family history (n = 2,814) Positive family history (n = 1,132)
High SES
(n = 429)
Middle SES
(n = 1,748)
Low SES
(n = 637)
High SES
(n = 220)
Middle SES
(n = 715)
Low SES
(n = 197)
Loco-regional therapy
BCS ? RT 271 (63%) 1,073 (61%) 336 (53%) 150 (72%) 474 (66%) 133 (68%)
Mastectomy 116 (27%) 448 (26%) 181 (28%) 54 (25%) 182 (26%) 45 (23%)
No surgery/BCS without RT 40 (9%) 225 (13%) 117 (18%) 8 (4%) 58 (8%) 19 (10%)
Unknown 2 (0.5%) 2 (0.1%) 3 (0.5%) 0 (0%) 1 (0.1%) 1 (0.5%)
*p \ 0.001 *p = 0.122
Chemotherapy
Yes 172 (40%) 680 (39%) 216 (34%) 89 (41%) 308 (43%) 85 (43%)
No 242 (56%) 1,019 (58%) 409 (64%) 128 (58%) 390 (55%) 110 (56%)
Unknown 15 (4%) 49 (3%) 12 (2%) 3 (1%) 17 (2%) 2 (1%)
*p = 0.029 *p = 0.721
Hormone therapy
Yes 255 (59%) 1,093 (63%) 418 (66%) 147 (67%) 468 (66%) 132 (67%)
No 125 (29%) 429 (25%) 125 (20%) 49 (22%) 180 (25%) 46 (23%)
Unknown 49 (11%) 226 (13%) 94 (15%) 24 (11%) 67 (9%) 19 (10%)
*p = 0.004 *p = 0.835
BCS breast-conserving surgery, RT radiotherapy
* p chi square of valid observations
Table 3 Impact of family history on probability of presenting with
screen/surveillance detected tumors, early stage disease at diagnosis,
receiving inadequate loco-regional treatment (no surgery, breast-
conserving surgery without radiotherapy), and chemotherapy accord-
ing to socio-economic status (SES)
Family
history
Detection by screening
or clinical examination
Early stage (0/I) at diagnosis Inadequate loco-regional
treatment
Chemotherapy
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)
Unadjusted
OR (95% CI)
Age-adjusted
OR (95% CI)
All patients
Negative 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Positive 1.30 (1.1–1.5) 1.32 (1.1–1.5) 1.01 (0.9–1.2) 1.00 (0.9–1.2) 0.53 (0.4–0.7) 0.68 (0.5–0.9) 1.21 (1.1–1.4) 1.01 (0.9–1.2)
Socio-economic status
High Negative 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Positive 1.03 (0.7–1.4) 1.07 (0.8–1.5) 1.08 (0.8–1.5) 1.08 (0.8–1.5) 0.52 (0.2–1.3) 0.75 (0.3–2.0) 1.02 (0.7–1.4) 0.91 (0.6–1.3)
Middle Negative 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Positive 1.27 (1.1–1.5) 1.30 (1.1–1.6) 0.96 (0.8–1.1) 0.95 (0.8–1.1) 0.50 (0.3–0.7) 0.63 (0.4–1.0) 1.19 (1.0–1.4) 1.04 (0.9–1.3)
Low Negative 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Positive 1.59 (1.1–2.3) 1.60 (1.1–2.3) 1.00 (0.7–1.4) 0.98 (0.7–1.4) 0.68 (0.4–1.2) 0.79 (0.4–1.4) 1.48 (1.1–2.3) 1.40 (1.0–2.1)
p value
interaction
between SES
and FH
0.29 0.29 0.27 0.81 0.64 0.82 0.28 0.21
OR odds ratio, SES socio-economic status, and FH is family history
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low SES were more likely to have their tumors detected by
screening if they had affected family members. This effect
was less pronounced in women of middle SES and absent
in high SES women. Low SES women at increased familial
risk were more likely to receive optimal loco-regional
treatment and chemotherapy when compared to low SES
women without a family history. In women of high and
middle SES, these effects were, again, less pronounced.
Surprisingly, the increased probability of low SES
patients to have their tumors detected by surveillance was
not accompanied by an increased likelihood of being
diagnosed with early stage disease. In addition, the dif-
ferent effect of family history on the proportion of screen
detected cancers and more optimal treatment across SES
strata did not translate into elimination of socio-economic
differences in breast cancer mortality risk. On the contrary,
only women of high and middle SES had a significant
reduction in breast cancer mortality risk in the presence of
a positive family history, whereas no significant association
between family history and mortality risk was seen in
women of low SES.
Previous studies on the impact of family history on
survival after breast cancer have yielded ambiguous results,
some indicating better, some similar, and some even worse
survival rates for patients with a positive family history
[25–27]. Differences in definition of family history, age-
related inclusion criteria, study design, definition of out-
come measures (overall survival versus disease specific or
disease free survival), and adjustment for confounders, as
well as limited sample size of studied populations, make
results of the various studies difficult to compare. In gen-
eral, most population-based studies including women of all
ages suggest a moderate protective effect of family history
before adjustment for confounders. In our study, we also
found a protective effect of a positive family history, which
was no longer significant after adjustment for stage and
diagnostic and treatment characteristics. This suggests that
better access to early detection and optimal treatment
among women with affected family members may partly
explain the survival benefit associated with a positive
family history.
Among women of low SES, the presence of a positive
family history increased the probability of them being
detected at an earlier stage and receiving adequate treat-
ment. It is, therefore, surprising that the impact of a posi-
tive family history on breast cancer mortality was the
lowest in this group. A possible explanation includes socio-
economic differences in life style. Unhealthy life style, in
particular obesity and low levels of physical exercise, are
increasingly being linked to adverse survival in breast
cancer patients [28–30]. As low SES is associated with
obesity, lower levels of physical exercise, and other
unhealthy life style patterns [31, 32], the beneficial effect
of improved access to screening and optimal treatment
associated with a positive family history may be counter-
acted by the higher prevalence of unfavorable life style
factors in breast cancer patients of low SES [33].
Another explanation could be that women of low SES
may have been more often receiving nonstandard treatment
regimens or suboptimal doses of chemotherapy. Griggs
Table 4 Impact of a positive family history on breast-cancer-specific mortality risk according to socio-economic status (SES)
Unadjusted
HR (95% CI)
Age-adjusted
HR (95% CI)
Multi adjusted
HR (95% CI)a
All patients
Negative family history 1 (ref) 1 (ref) 1 (ref)
Positive family history 0.69 (0.6–0.9)* 0.74 (0.6–0.9)* 0.84 (0.7–1.05)
By socio-economic status
High SES
Negative family history 1 (ref) 1 (ref) 1 (ref)
Positive family history 0.48 (0.3–0.9)* 0.54 (0.3–1.0)* 0.58 (0.3–1.1)
Middle SES
Negative family history 1 (ref) 1 (ref) 1 (ref)
Positive family history 0.74 (0.6–1.0)* 0.77 (0.6–1.0)* 0.92 (0.7–1.2)
Low SES
Negative family history 1 (ref) 1 (ref) 1 (ref)
Positive family history 0.77 (0.5–1.2) 0.80 (0.5–1.2) 0.85 (0.5–1.3)
p value for interaction between
SES and family history
0.45 0.47 0.36
SES socio-economic status and HR hazard ratio
* p \ 0.01
a Adjusted for age, stage, grade, estrogen receptor status, method of detection, loco-regional therapy, and chemotherapy
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et al. [34] have shown that women with a low level of
education are more than three times as likely to receive
nonstandard chemotherapy regimens compared to women
with a high level of education. In addition, obese and
overweight breast cancer patients often receive intention-
ally reduced doses of chemotherapy, because of fear of
excessive toxic effects [34]. Because the prevalence of
obesity is higher among women of low SES [32, 33], these
women could be at increased risk of suboptimal dosing. So
even though in our study, women of low SES with a family
history received significantly more often chemotherapy
than those without affected family members, the survival
benefit associated with adjuvant chemotherapy could have
been reduced when optimal doses of chemotherapy have not
been given. Unfortunately, we did not have information on
type and dose of chemotherapy administered in our study.
A recent study from the Netherlands showed that
women of high SES benefitted more from introduction of
mass mammography screening, in terms of survival, than
lower SES groups [35]. Even though survival rates of all
SES groups improved significantly between 1983 and 1990
and 1997–2002 in the South of the Netherlands (where a
population-based screening program was introduced in
1991), significantly higher increases in survival were seen
in women of high SES (from 69 to 89% 5-year cumulative
survival) than in women of low SES (from 70 to 80%
5-year cumulative survival). The authors proposed that
lower survival rates might be attributed to suboptimal
treatment and poorer life style habits. As co-morbidity
impairs relative survival of breast cancer [36], higher co-
morbidity rates among women of low SES could have
increased their mortality risks as well. Because the Geneva
Cancer Registry does not systematically register informa-
tion on co-morbidity, we were not able to take the impact
of this possible confounder into account.
We acknowledge that our study suffers from several
limitations. Firstly, the limited sample size, especially in
the subgroups of women with positive family histories and
high or low SES, has led to less precise estimates in these
subgroups and may explain lack of significance of some of
our results. We used the patient’s most recent occupation
as registered at the Cantonal Population Office (the only
measure of SES available for our study) to categorize
patients into high, middle, and low SES groups. We
acknowledge that, although it was collected at an individ-
ual level, occupation may not be sufficient to capture the
multidimensional nature of SES, as it is also influenced by
educational level, ethnicity, and many other factors.
Inconsistent or inadequately measuring of socio-economic
factors may affect conclusions about the relationship
between SES and health outcomes. In addition, no infor-
mation on SES was available for a large proportion of
women (mainly housewives), which therefore had to be
excluded from the study. However, in a previous study we
found that breast cancer patients with unknown SES were
rather comparable to those of middle SES in terms of tumor
characteristics, diagnostic and treatment patterns, and
breast cancer mortality risks [10]. To check whether this
comparability was also true for this study, we performed a
sensitivity analysis, regrouping the women with unknown
SES with those of middle SES. This hardly affected the
results, except for some small changes (\6%) in some
Hazard Ratios in Table 4.
Our definition of a positive family history was based on
the presence of first- or second-degree relatives with breast
or ovarian cancer [1, 2]. Nevertheless, the presence of only
ovarian cancer in family members may not have as strong
an effect on awareness of the disease and preparedness for
therapy as the presence of a breast cancer among family
members. In our study, out of the 1,132 patients with a
positive family history, 33 (\3%) were classified as such
based only on family members affected with ovarian can-
cer. Re-analysis of the data with exclusion of these 33
patients did not significantly alter any of the results. We
recognize that there could be an association between SES
and the level of patients’ knowledge on their family history
and accuracy of reporting. We were not able to check for
this, but a previous validation study from our institute
showed that in general, family history of breast cancer is
reported rather accurately [17]. Finally, 10% of our patient
population had missing information on family history. This
could have affected our results to a certain extent, if there
was an association between actual presence or absence of a
family history and the likelihood of it being accurately
recorded.
Reasons for better breast-cancer-specific survival among
women of high SES has never been completely elucidated.
Indeed, better access to early detection and state of the art
therapy are likely to explain part of the survival benefit of
women of high SES (12). The results of the current study
suggest that better awareness due to a positive family
history may play a role as well. In this study, we have
shown that women of high SES were more likely to have
family members with breast or ovarian cancer. Our results
also suggest a positive association between family history
and outcome after breast cancer. If confirmed by others, the
higher prevalence of positive family history among women
of high SES could partly explain the mechanism behind the
better survival after breast cancer in high SES women.
In conclusion, the presence of a positive family history
eliminates SES differences in access to screening and
optimal treatment. However, this does not translate into
reduction in SES differences in breast cancer mortality
risks. Even with better access to early detection and more
optimal treatment, women of low SES still have higher
risks of death from their disease than those of high SES.
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